



NMS Labs

CONFIDENTIAL

200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com

Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

Demo Report

Report Issued 03/30/2020 12:06
Last Report Issued 05/22/2015 06:42

88888
Clinical Example Report
Attn: Example Reports
200 Welsh Road
Horsham, PA 19044

Patient Name 1812B
Patient ID 1812B
Chain 15001053
Age Not Given **DOB** Not Given
Gender Not Given
Workorder 15001053
Received 05/22/2015 06:39

Sample ID 15001053-001
Matrix Blood
Patient Name 1812B
Patient ID 1812B
Container Type Clear vial

Collect Dt/Tm Not Given
Source Not Given

Approx Vol/Weight Not Given

Receipt Notes None Entered

| Analysis and Comments | Result | Units | Reporting Limit | Notes |
|-----------------------|--------|-------|-----------------|-------|
|-----------------------|--------|-------|-----------------|-------|

1812B Donepezil, Blood

Analysis by High Performance Liquid Chromatography/
Tandem Mass Spectrometry (LC-MS/MS)

| | | | | |
|-----------|---------------|-------|-----|--|
| Donepezil | None Detected | ng/mL | 5.0 | |
|-----------|---------------|-------|-----|--|

Synonym(s): Aricept®

Acetylcholinesterase inhibition (50 - 90%) has been observed at steady-state plasma concentrations between 15 - 50 ng/mL. Steady-state levels are achieved after approximately 2 weeks of daily dosing.

This test was developed and its performance characteristics determined by NMS Labs. It has not been cleared or approved by the US Food and Drug Administration.